Molecular Epidemiology of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in south Ethiopia.
Adolescent
Adult
Antitubercular Agents
/ pharmacology
Cross-Sectional Studies
Demography
Ethiopia
/ epidemiology
Female
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Molecular Typing
Mycobacterium tuberculosis
/ drug effects
Tuberculosis, Multidrug-Resistant
/ drug therapy
Tuberculosis, Pulmonary
/ drug therapy
Young Adult
Ethiopia
Molecular epidemiology
Tuberculosis
drug susceptibility testing
geospatial cluster
Journal
Journal of infection in developing countries
ISSN: 1972-2680
Titre abrégé: J Infect Dev Ctries
Pays: Italy
ID NLM: 101305410
Informations de publication
Date de publication:
30 09 2021
30 09 2021
Historique:
received:
20
01
2021
accepted:
04
03
2021
entrez:
20
10
2021
pubmed:
21
10
2021
medline:
15
1
2022
Statut:
epublish
Résumé
Understanding the epidemiology of tuberculosis is limited by lack of genotyping data. We sought to characterize the drug susceptibility testing patterns and genetic diversity of M. tuberculosis isolates in southern Ethiopia. A cross-sectional study was conducted among newly diagnosed sputum smear positive patients with tuberculosis visiting nine health facilities in southern Ethiopia from June 2015 to May 2016. Three consecutive sputum samples (spot-morning-spot) per patient were examined using acid-fast bacilli smear microscopy with all smear positive specimens having acid-fast bacilli cultures performed. M. tuberculosis isolates had drug susceptibility testing performed using indirect proportion method and were genotyped with RD9 deletion analysis and spoligotyping. Mapping of strain was made using geographic information system. Among 250 newly diagnosed patients with tuberculosis, 4% were HIV co-infected. All 230 isolates tested were M. tuberculosis strains belonging to three lineages: Euro-American, 187 (81%), East-African-Indian, 31 (14%), and Lineage 7 (Ethiopian lineage), 8 (4%); categorized into 63 different spoligotype patterns, of which 85% fell into 28 clusters. M. tuberculosis strains were clustered by geographic localities. The dominant spoligotypes were SIT149 (21%) and SIT53 (19%). Drug susceptibility testing found that 14% of isolates tested were resistant to > 1 first line anti- tuberculosis drugs and 11% to INH. SIT 149 was dominant among drug resistant isolates. The study revealed several clusters and drug resistant strains of M. tuberculosis in the study area, suggesting recent transmission including of drug resistant tuberculosis. Wider monitoring of drug susceptibility testing and geospatial analysis of transmission trends is required to control tuberculosis in southern Ethiopia.
Identifiants
pubmed: 34669600
doi: 10.3855/jidc.14742
pmc: PMC8556644
mid: NIHMS1750540
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1299-1307Subventions
Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Informations de copyright
Copyright (c) 2021 Yared Merid, Elena Hailu, Getnet Habtamu, Melaku Tilahun, Markos Abebe, Mesay Hailu, Tsegaye Hailu, Daniel Gemechu Datiko, Yimtubezinash Woldeamanuel, Abraham Aseffa.
Déclaration de conflit d'intérêts
No Conflict of Interest is declared
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 1994 Jun 16;330(24):1703-9
pubmed: 7910661
J Clin Microbiol. 1997 Apr;35(4):907-14
pubmed: 9157152
Int J Tuberc Lung Dis. 2013 Feb;17(2):246-50
pubmed: 23317962
Clin Microbiol Rev. 2016 Apr;29(2):239-90
pubmed: 26912567
Lancet Infect Dis. 2007 May;7(5):328-37
pubmed: 17448936
Curr Biol. 2015 Dec 21;25(24):3260-6
pubmed: 26687624
Sci Rep. 2018 Mar 5;8(1):3987
pubmed: 29507363
J Med Microbiol. 2010 Mar;59(Pt 3):285-294
pubmed: 19959631
BMC Res Notes. 2014 Aug 10;7:512
pubmed: 25108648
BMC Res Notes. 2012 May 10;5:225
pubmed: 22574696
Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 1:8-13
pubmed: 21420561
Int J Tuberc Lung Dis. 2012 Jun;16(6):805-11
pubmed: 22390880
Afr Health Sci. 2012 Sep;12(3):339-44
pubmed: 23382750
J Clin Microbiol. 2002 Jul;40(7):2339-45
pubmed: 12089245
New Microbes New Infect. 2017 Mar 03;17:69-74
pubmed: 28377803
Tuberc Res Treat. 2014;2014:753492
pubmed: 24834351
PLoS Med. 2015 Sep 29;12(9):e1001880
pubmed: 26418737
Infect Genet Evol. 2017 Nov;55:251-259
pubmed: 28919549
Infect Drug Resist. 2018 Sep 25;11:1581-1589
pubmed: 30288068
Trop Dis Travel Med Vaccines. 2018 Dec 4;4:15
pubmed: 30534412
Indian J Med Microbiol. 2017 Jan-Mar;35(1):27-32
pubmed: 28303814
Emerg Infect Dis. 2013 Mar;19(3):460-3
pubmed: 23622814
J Infect Dev Ctries. 2012 Jan 12;6(1):33-9
pubmed: 22240426
J Clin Microbiol. 2015 Apr;53(4):1301-9
pubmed: 25673798
BMC Infect Dis. 2018 Mar 27;18(1):140
pubmed: 29587640
PLoS One. 2018 Feb 15;13(2):e0193083
pubmed: 29447273